Citations

Clear

199 citation(s) found for "Lu, Cathy".

Revisiting Centiloids using AI
Bourgeat, Pierrick , Xia, Ying , Feizpour, Azadeh , Zisis, Georgios , Goyal, Manu S. , Tosun, Duygu , Short, C, Adam, Robert , Robertson, Joanne, Park, Denise C. , Farrar, Gill , Bollack, Ariane , Landau, Susan , Koeppe, Robert, Morris, John, Weiner, Michael, Villemagne, Victor L. , Masters, Colin, Doré, Vincent , Xia, Ying , Feizpour, Azadeh , Goyal, Manu , Tosun, Duygu , Benzinger, Tammie L S , LaMontagne, Pamela , Sperling, Reisa Anne , O'Bryant, Sid , Johnson, Sterling C. , Jack, Clifford R , Schwarz, Christopher G , Park, Denise C , Collij, Lyduine , Rowe, Christopher Cleon , Doré, Vincent , Bourgeat, Pierrick , Fripp, Jürgen , Lebrat, Léo , Cox, Timothy O. , Gillman, Ashley , Benzinger, Tammie L.S. , Breakspear, Michael J , Lupton, Michelle K. , Short, Cathy, O’Bryant, Sid E. , Jack, Clifford R. , Schwarz, Christopher G. , Barkhof, Frederik , Masters, Colin

Mayo Clinic

No container title available | July 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7015694/v1 | PMID 40671806 Get It

Abstract The Centiloid scale is the standard for Amyloid (Aβ) PET quantification, widely used in research, clinical settings, and trial stratification. However, variability between tracers and scanners remains a challenge. This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalising implausible longitudinal trajectories during training. The model was trained using data from 2,098 participants (6,762 Aβ PET scans) in AIBL/ADNI and validated using 15,806 Aβ PET scans from 10,543 participants across 10 external datasets. DeepSUVR increased correlation between tracers, and reduced variability in the Aβ-negatives. It showed the strongest association with cognition, highest AUC against visual reads and best longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting lower Centiloid increase per year in the A4 study. DeepSUVR advances Aβ PET quantification, outperforming standard approaches, which is particularly important for consistent decision making and to detect subtle and early changes in clinical interventions.
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
Élez, Elena , Shen, Lin , Kim, Tae Won, Yaeger, Rona , Usari, Tiziana, Laliberte, Robert J, Dychter, Samuel S., Zhang, Xiaosong , Yoshino, Takayuki , Lonardi, Sara , Cutsem, Eric Van , Eng, Cathy , Kim, Tae Won, Wasan, Harpreet , Desai, Jayesh , Ciardiello, Fortunato , Maughan, Tim , Morris, Van K. , Wu, Christina N. , Tabernero, Josep , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | June 4, 2025 | Volume: 43 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2025.43.17_suppl.lba3500 Get It

LBA3500 Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ± chemotherapy (chemo) vs standard of care (SOC; chemo ± bevacizumab) in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study previously met one of its dual primary endpoints (EPs) demonstrating clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) by blinded independent central review (BICR) in the ORR subset. These results were the basis for the FDA accelerated approval of EC+mFOLFOX6 for BRAF V600E-mutant mCRC, including in the 1L, under Project Frontrunner. Here, we report the primary analysis of progression-free survival (PFS) by BICR, updated interim analysis of OS, updated safety, and other analyses. Methods: Eligible patients (pts) with untreated BRAF V600E-mutant mCRC were randomized 1:1:1 to receive EC, EC+mFOLFOX6, or SOC; EC arm enrollment was closed after a protocol amendment. Dual primary EPs: ORR and PFS by BICR (EC+mFOLFOX6 vs SOC); key secondary EP: OS (EC+mFOLFOX6 vs SOC). Results: 637 pts were randomized to EC, EC+mFOLFOX6, or SOC. Baseline demographics and disease characteristics were generally balanced between arms. EC+mFOLFOX6 (data cutoff: Jan 6, 2025) demonstrated a clinically meaningful and statistically significant PFS improvement vs SOC, meeting the other dual primary EP; HR=0.53 (95% CI 0.407, 0.677; P<0.0001); median PFS 12.8 vs 7.1 mo. OS was clinically meaningful and statistically significant vs SOC; HR=0.49 (95% CI 0.375, 0.632; P<0.0001); median OS 30.3 vs 15.1 mo. Median PFS and OS in the EC arm were 6.8 and 19.5 mo. These data and response data for all randomized pts are shown in the table. Serious treatment-emergent adverse events occurred in 30%, 46%, and 39% of pts in the safety analysis set. Safety was consistent with that known for each agent. Conclusions: BREAKWATER demonstrated clinically meaningful and statistically significant PFS and OS improvements with EC+mFOLFOX6 vs SOC and manageable toxicities. EC+mFOLFOX6 is potentially practice changing as the new SOC. Clinical trial information: NCT04607421 . ECn=158 EC+mFOLFOX6n=236 SOCn=243 EC+mFOLFOX6vs SOCHR (95% CI)P-value a Median PFS b , mo (95% CI) 6.8(5.7, 8.3) 12.8(11.2, 15.9) 7.1(6.8, 8.5) 0.53 (0.407, 0.677) <0.0001 Median OS, mo (95% CI) 19.5(17.6, 22.5) 30.3(21.7, NE) 15.1(13.7, 17.7) 0.49 (0.375, 0.632)<0.0001 ORR, b % (95% CI) 45.6(38.0, 53.3) 65.7(59.4, 71.4) 37.4(31.6, 43.7) Median DOR b , mo (95% CI) c 7.0 (4.2, 11.6) 13.9 (10.9, 18.5) 10.8 (7.6, 13.4) DOR b ≥6 mo, n (%) c 29 (40.3) 110 (71.0) 38 (41.8) DOR b ≥12 mo, n (%) c 15 (20.8) 54 (34.8) 16 (17.6) Median time to response, b wk (range) c 6.6(4.3-86.4) 7.0(5.1-103.6) 7.3 (5.4-48.0) a 1-sided stratified log rank test. b By BICR. c Responders: n=72, n=155, and n=91. DOR, duration of response.
BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine clinical trials.
Spencer, Kristen , Ulrickson, Matthew L. , Grierson, Patrick , Patel, Sandip Pravin , Specht, Jennifer M. , Morelli, Maria Pia , Maloney, David G. , Weng, Wen-Kai, Waschke, Brittany, Ng, Eric Wai-Choi , Tebbets, Jessica , Hecht, J. Randolph, Molina, Julian R. , Specht, Jennifer , Park, Jong Chul , Murthy, Hemant S. , Simeone, Diane M. , Maus, Marcela V , Weng, Wen‐Kai , Eng, Cathy , He, Kai , Kirtane, Kedar

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e23020 Get It

e23020 Background: Precision medicine studies must overcome the challenges of identifying patients with uncommon molecular targets and small cohort sizes for correlative studies. BASECAMP-1 (NCT04981119) is a prescreening study that uses a single assay to address both problems by: 1) efficiently screening potentially eligible patients for subsequent clinical trials of Tmod logic-gated chimeric antigen receptor T-cell (CAR T) therapies; and 2) providing a large dataset available for translational studies. Methods: Initially, patients were identified for BASECAMP-1 by consenting and genotyping all potentially eligible patients for human leukocyte antigen (HLA)-A*02 heterozygosity. To improve screening efficiency, we co-developed a patient-matching program with Tempus AI, Inc (Tempus), in which Tempus informs the principal investigators of next-generation sequenced (NGS) patients with HLA-A*02 heterozygosity within their health system who may be eligible for BASECAMP-1. Patients are screened using the Tempus xT platform, which uses genomic and RNA sequencing (RNAseq) analyses to determine gene mutations and expression. Enrolled patients with colorectal (CRC), non-small cell lung, ovarian (OVCA), and pancreatic cancers (PANC) were analyzed for tumor purity, mutation distribution, HLA-A*02 loss of heterozygosity (LOH) status, and RNAseq to validate the data available for future clinical analyses. Results: As of January 3, 2025, 80 participants have been enrolled in BASECAMP-1. Through individual screening methods, 1684 patients were screened at 13 study sites, of which 30 patients had tumor-specific HLA-A*02 LOH and were enrolled (~1 eligible patient identified per 56 screened). The patient-matching program identified 282 patients with HLA-A*02 LOH at 12 sites; of these, 50 consented to the BASECAMP-1 study (~1 patient enrolled per 6 identified), demonstrating higher efficiency than the individual patient screening method. Correlative data from xT were available for 360 patients with germline HLA-A*02 and provided insights into mutational distribution and target expression. LOH status was not associated with tumor-specific differences in missense mutational distribution. RNAseq data demonstrated higher CEACAM5 expression in CRC and higher MSLN in PANC and OVCA vs other tumor types, while EGFR was consistently expressed with reduced variance across tumor types, confirming these as potential target antigens for Tmod CAR T interventional trials EVEREST-1, EVEREST-2, and DENALI-1. Conclusions: Identification and enrollment of HLA-A*02 LOH patients into BASECAMP-1 for logic-gated CAR T therapeutic studies were accelerated by the patient matching program. Concurrent xT analysis provides opportunities to augment analyses from robust propensity-matched comparisons, response correlation studies, and other translational discovery. Clinical trial information: NCT04981119 .
0421 Detecting Central Sleep Apnea Using a Multi-Diagnostic Chest-Worn Monitor
Dupuy-McCauley, Kara , Molavi, Behnam , Sharma, Surina , Collop, Nancy A. , Goldstein, Cathy , Rosen, Ilene M. , Khayat, Rami

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A185-A185

10.1093/sleep/zsaf090.0421 Get It

Abstract Introduction Identifying central sleep apnea (CSA) during home sleep apnea testing is important to guide appropriate treatment for sleep-disordered breathing (SDB) and underlying cardiovascular conditions, including heart failure and atrial fibrillation. SANSA (Huxley Medical, Inc.) is a multi-diagnostic chest-worn monitor capable of detecting SDB, cardiac arrhythmias, and heart function. Using polysomnography (PSG) as a reference, we developed a machine learning (ML) method to classify respiratory events from this monitor as central or obstructive. Methods Data was analyzed from ninety-five subjects with suspected SDB who wore the chest monitor simultaneously with PSG overnight. To address known scoring heterogeneity of CSA, PSG records were scored for central apneas by two core laboratories (Core 1 and Core 2). Core 1 annotations from twenty-eight records were first used to train a random forest classifier to differentiate obstructive (N=680) and central events (N=388). The model used oximetry, respiratory effort, and snoring to classify events based on effort, duration, and other features. A five-fold cross validation was used to evaluate event-level performance. The model was then used to estimate subject-level CAI for all subjects and compared with Core 2 scores. Results Algorithm event-level sensitivity and specificity to detect central events was 72.7% and 81.0%. Subject-level CAI for all records between the chest monitor and Core 2 had a correlation coefficient of 0.90 and root mean squared error (RMSE) of 4.6 events/hour, versus 0.82 and 4.7 events/hour comparing Core 1 and Core 2. Sensitivity and specificity to detect CAI≥10 events/hour was 80.0% (4/5) and 98.9% (89/90), compared to 100% (3/3) and 98.9% (91/92) for CAI≥15. Conclusion An ML algorithm to differentiate obstructive and central events collected from the chest-worn monitor demonstrated favorable event-level performance and comparable CAI agreement to that between two PSG core laboratories. Home-based CSA detection alongside cardiac monitoring could identify high risk patients for expedited therapy, cardiology referral, or follow-up PSG. These results motivate further validation in a larger cohort as well as investigation of outcomes related to time to evaluation and management. Support (if any) National Science Foundation; Georgia Research Alliance; Huxley Medical, Inc.
Baseline Dyspnea Associated With Risk for Severe Features of Bronchiectasis Phenotype in the US Bronchiectasis and Nontuberculous Mycobacterium Research Registry
Ignatius, Elisa H. , Aksamit, Timothy R. , Geyer, A, Richards, Cathy, Winthrop, K.L., Yohannes, Abebaw Mengistu , Brunton, Amanda E. , Choate, Radmila , Maselli, Diego J , Swenson, Colin , Richards, C.J., Solomon, George M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7282-A7282

10.1164/ajrccm.2025.211.abstracts.a7282 Get It

Abstract Introduction Persistent dyspnea increases the risk of disability and impairs quality of life in older patients with bronchiectasis. The impact of dyspnea and fatigue on patients with bronchiectasis in long term follow-up has not been adequately established. We sought to determine if fatigue and higher-grade dyspnea are associated with worse clinical outcomes in 5-years of longitudinal follow-up. Methods We analyzed data collected from a prospective cohort of adult patients with bronchiectasis enrolled in the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry. Patients with a modified Medical Research Council (mMRC) dyspnea score collected at baseline and during 3-5 years of follow-up were included and stratified as mMRC&lt;2 versus mMRC ≥2. Kruskal-Wallis, independent sample t-tests and chi-square tests were used to test the differences in medians and means for continuous variables and associations between categorical variables, respectively, between the baseline mMRC groups and bronchiectasis severity index (BSI) components at follow-up. A multivariable logistic regression analysis was performed to determine the association between dyspnea and clinical outcomes (exacerbations and hospitalizations) at follow-up. Results 1185 adult patients with bronchiectasis met the inclusion criteria. The median age (interquartile range) was 76 (68 to 83) years. At baseline, patients with mMRC ≥2 had a higher proportion of co-existing diagnoses such as asthma, chronic obstructive pulmonary disease (COPD), otitis/rhinosinusitis, rheumatologic disease, and pneumonia compared to patients with mMRC &lt;2 (all p&lt;0.05, data not shown). Furthermore, patients with mMRC &gt; 2 compared to patients with mMRC &lt;2 had higher prevalence of fatigue, acute exacerbations and pulmonary related hospitalizations, and lower mean percentage predicted forced expiratory volume in one second (FEV1) at follow-up (all p&lt; 0.05) (Table 1). Interestingly, body mass index was slightly higher among those with baseline mMRC ≥2 compared to mMRC &lt;2 (p=0.02). Among those with mMRC ≥2 at both baseline and follow-up (n=67, 42%), the odds of having ≥1 exacerbation was 2.4 times higher (odds ratio [OR] 2.45, 95% confidence interval [CI] 1.45-4.1) and 2.8 times higher for ≥1 hospitalization (OR 2.8, 95% CI 1.45-5.2) during follow-up after adjusting for fatigue. Conclusion Elevated dyspnea was associated with a greater proportion of patients with bronchiectasis exhibiting acute exacerbations and pulmonary related hospitalizations and lower lung function during follow-up. Research is still needed to understand the causes (drivers) of dyspnea to implement better treatment strategies and reduce adverse outcomes in bronchiectasis patients.
Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Singh, Jasvinder A. , Eisen, Seth A. , Chatham, Winn, Narain, Sonali , Kamen, Diane L. , Trotter, Kimberly , Majithia, Vikas , Ching, Cathy Lee , Aouhab, Zineb , Venuturupalli, Swamy, McMahon, Maureen , Bhairavarasu, Kalpana, Beasley, Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Jackson, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana, Eisen, Seth , Narain, Sonali , Kamen, Diane L , Trotter, Kimberly , Majithia, Vikas , Lee Ching, Cathy , Ramsey-Goldman, Rosalind , Kim, Alfred H J , McMahon, Maureen , Lim, S Sam , Meara, Alexa Simon , Singh, Jasvinder A , Hearld, Larry R. , Annapureddy, Narender , Venuturupalli, Swamy, Wallace, Daniel J , Ramsey‐Goldman, Rosalind , Kim, Alfred H.J. , Lim, S. Sam , Bhairavarasu, Kalpana, Kalunian, Kenneth , Beasley, Timothy Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana

Mayo Clinic

Rheumatology | April 13, 2025 | Volume: 64 | Issue: 8 | Pages: 4631-4640

10.1093/rheumatology/keaf205 | PMID 40221856 Get It

Abstract Objective The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. Methods We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019–2024 (including the COVID pandemic). We undertook Organizational Readiness to Implement Change Surveys (ORICs) and Team Learning and Psychological Safety Surveys (TLPSSs) at baseline. The primary study outcome objective measure, percent penetration/reach, was defined as the number of patients who viewed the lupus PtDA at the end of the study, divided by the total number of eligible patients (times 100). We used validated clinical personnel surveys to examine the perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4 months, 12 months and 24 months post-PtDA implementation. Results Among the sites, the clinical personnels’ (n = 184) baseline ORIC commitment and efficacy scores (a 0–5 scale, higher = better) ranged from 3.5 to 4.2, and 3.4 to 4.4, respectively; the TLPSS scores (a 0–7 scale, higher = better) were 3.9–5.5 for internal learning, 3.7–5.6 for external learning, and 4.3–5.5 for psychological safety. The penetration (primary outcome) among 15 geographically diverse US rheumatology clinics ranged from 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinical personnel–perceived lupus PtDA outcomes were optimal at 4 months (all scale scores ranged from 1 to 5, higher = better): (i) appropriateness, 3.43 (s.d. 0.86); (ii) acceptability, 3.53 (s.d. 0.83); (iii) feasibility, 3.44 (s.d. 0.71); (iv) success, 3.41 (s.d. 0.73); and (v) permanence, 3.22 (s.d. 0.74). Conclusion We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months. Trial Registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT03735238.
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations
Storandt, Michael H. , Shi, Qian , Lieu, Christopher H. , George, Thomas J. , Stoppler, Melissa C. , Mauer, Elizabeth , Teslow, Emily A. , Mahipal, Amit , Jin, Zhaohui , Lieu, Christopher , George, Thomas J , Teslow, Emily A , Mahipal, Amit , Jin, Zhaohui , Shi, Qian , Eng, Cathy , Yilma, Binyam , Fragkogianni, Stamatina

Mayo Clinic

Cancers | February 28, 2025 | Volume: 17 | Issue: 5 | Pages: 836

10.3390/cancers17050836 | PMID 40075683 Get It

Background: Rates of early-onset colorectal cancer (eoCRC), defined as disease diagnosed at <50 years of age, are increasing. The incidence and spectrum of somatic and pathogenic germline variants (PGV) in this population are not well understood. Methods: This cross-sectional study leveraged Tempus’ clinicogenomic database, including de-identified records of patients diagnosed with CRC between 2000–2022, to analyze and compare eoCRC and average-onset colorectal cancer (aoCRC, disease diagnosed ≥50 years of age) patients. The frequency and spectrum of somatic mutations and PGVs in patients with eoCRC and aoCRC were evaluated and compared. Results: Among 11,006 participants in this study, 57% were male, 76% were white, and 80% had stage 4 disease. Within the total cohort, 2379 had eoCRC and 8627 had aoCRC. Among patients with eoCRC, 4.2% had a tumor with high microsatellite instability and/or deficient mismatch repair (MSI-H/dMMR) and 6.8% with aoCRC had an MSI-H/dMMR tumor (p < 0.001). The most frequent somatic mutations involved TP53, APC, and KRAS, with the most significant difference in BRAF, which was more frequently mutated in aoCRC (9.8% vs. 4.7%, p < 0.0001). In total, 1413 (59.4%) eoCRC and 4898 (56.8%) aoCRC patients had matched normal specimen (blood or saliva) sequencing and a PGV was identified in 6.9% of eoCRC and 5.0% of aoCRC patients. Conclusions: Somatic and germline mutation profiles were similar for eoCRC and aoCRC patients and may not adequately explain differences in tumor behavior and age of disease onset.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Inaba, Hiroto , Teachey, David T. , Annesley, Colleen , Batra, Sandeep , Beck, Jill C., Cooper, Stacy , Dallas, Mari , Oliveira, Satiro De , Kelly, Kara M. , Kohorst, Mira A. , Kutny, Matthew A. , Lee‐Miller, Cathy , Ludwig, Kathleen , Madden, Lisa, Maloney, Kelly W. , Massaro, Stephanie, Morocco, Perry , Muller, Brad, Murphy, Lindsey , Nardi, Valentina , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Wong, Victor , Yanik, Gregory A. , Stehman, Katie, Inaba, Hiroto , Colace, Susan I. , Kitko, Carrie L. , Lacayo, Norman James , Mangum, David Spencer , McCall, David C. , Shah, Bijal , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 41-62

10.6004/jnccn.2025.0006 | PMID 39938467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.
EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss o
Spencer, Kristen , Grierson, Patrick , Mitchell, Jasmine , Lin, Yi , Vu, Peter , Morelli, Maria Pia , Kundranda, Madappa N. , Dorigo, Oliver , Maloney, David G. , Ward, Jeffrey D. , Welch, John S. , Molina, Julian R. , Go, William Y., Hecht, J. Randolph, Punekar, Salman R. , Castria, Tiago Biachi De , Zhen, David B. , Ward, Jeffrey, Eng, Cathy , Maus, Marcela V , Simeone, Diane M.

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: No page available

10.1200/jco.2025.43.4_suppl.tps788 Get It

TPS788 Background: MSLN is a desirable candidate for targeted therapy given its limited expression in normal tissues and its overexpression in several malignancies, including PANC, mesothelioma, non-small cell lung, and ovarian cancers (TCGA 2022). MSLN-targeted CAR T and T-cell receptor therapies have shown promising clinical activity; however, on-target, off-tumor toxicity, including fatal events, have occurred (1-3). Autologous logic-gated Tmod CAR T therapies address the challenges of on-target, off-tumor toxicity by combining 2 CARs: activating and blocking receptors. The activator recognizes a tumor-associated antigen present on the surface of both tumor and normal cells; the blocker prevents CAR T activity when it binds HLA-A*02, which is present in normal cells and often lost in tumor cells. Thus, in patients with tumor-associated HLA-A*02 LOH, the blocker prevents on-target, off-tumor toxicity on normal cells due to retained HLA-A*02 expression (4). HLA-A*02 LOH is observed in various solid tumors, including ~20% of PANC (5). Two autologous CAR T therapies are currently under investigation: A2B530, targeting carcinoembryonic antigen, in the EVEREST-1 trial, and A2B694, targeting MSLN, in the EVEREST-2 trial, described herein. A2B694 may provide a therapeutic window to treat patients with PANC and other MSLN-expressing solid tumors exhibiting HLA-A*02 LOH due to its unique discriminatory mechanism. Methods: EVEREST-2 (NCT06051695) is a first-in-human, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B694 for recurrent unresectable, locally advanced, or metastatic cancers with MSLN expression, including PANC. Eligible patients must have exhausted options of potentially curative therapy and have recurrent disease. Enrollment to EVEREST-2 occurs through the prescreening study BASECAMP-1 (NCT04981119), in which patients with tumor-associated HLA-A*02 LOH are identified via next-generation sequencing (Tempus AI, Inc) and leukapheresis product is collected. A2B694 is manufactured from cryopreserved T cells when clinically appropriate for patients. The primary objective of phase 1 is to evaluate the safety and tolerability of A2B694 and identify the recommended phase 2 dose (RP2D). The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B694. Phase 2 will assess the primary endpoint overall response rate per RECIST v1.1 and secondary endpoints progression-free survival and overall survival. The first patient was dosed on April 24, 2024 and dose escalation is ongoing. 1. Beatty, et al. Gastroenterology . 2018. 2. Haas, et al. Mol Ther . 2023. 3. Hong, et al. ESMO 2021. Abstr 9590. 4. Hamburger, et al. Mol Immunol . 2020. 5. Hecht, et al. J Clin Oncol . 2022. Clinical trial information: NCT06051695 .